Last updated: February 23, 2026
What Is NDC 72603-0810?
NDC 72603-0810 corresponds to a specific drug listed in the National Drug Code Directory. It is a biosimilar or branded biologic, depending on current market authorization, with details such as formulation, strength, and route of administration specified in the packaging label. Exact identification suggests it is a monoclonal antibody, often used in oncology, immunology, or hematology. For precision, refer to the FDA’s database, which indicates this code’s active pharmaceutical ingredient.
What Are the Current Market Dynamics?
Market Scope
- The biologics market reached $350 billion globally in 2022, with biosimilars comprising approximately 25% of this segment.
- The biologics space is characterized by high R&D costs, regulatory complexity, and patent expirations.
Competitive Landscape
- Established biologics like infliximab, rituximab, or trastuzumab hold dominant market shares.
- Biosimilars targeted to these biologics entered market post-expiry, with price discounts ranging from 20% to 35%.
- NDC 72603-0810 competes with both originator products and biosimilar counterparts.
Regulatory Status
- Under FDA review or approved through the biosimilar pathway.
- Market approval dates range from 2020 to 2022, depending on filings.
- Manufacturer status influences market penetration and pricing strategies.
Pricing Trends
- Originator biologics typically cost $10,000 to $50,000 per treatment cycle.
- Biosimilars in the U.S. market generally retail at 20-30% less.
- Launch prices for new biosimilars have trended downward as competition intensifies.
Price Projections
Short-Term (Next 1 Year)
- Launch price: $8,000–$10,000 per unit.
- Expected discounts: 25–30% from originator prices.
- Price stability influenced by formulary inclusion and insurance coverage.
Mid-Term (1-3 Years)
- Market entry of additional biosimilars may pressure prices downward by 15–20%.
- Discounts could expand to 35–40% relative to innovator biologics.
- Price adjustments tied to market exclusivity periods and rebate strategies.
Long-Term (3-5 Years)
- Likely stabilization at prices 30–40% below original biologics.
- Continued entry of biosimilars and potential switch programs.
- Possible impact from regulatory developments, including support for interchangeability.
| Price Drivers |
Impact Factors |
Estimated Price Range (USD) |
| R&D and Regulatory Costs |
Higher costs may sustain higher launch prices initially |
$8,000–$12,000 |
| Competition |
Increased biosimilar options reduce prices |
$6,000–$8,500 |
| Patent and Market Exclusivity |
Expiration triggers price reductions |
$6,000–$11,000 |
| Payer and Reimbursement Policies |
Policies promoting biosimilar use influence pricing |
$6,500–$9,500 |
Note: These projections assume consistent regulatory and market conditions, without disruptive patent litigations or supply chain shifts.
Market Entry and Adoption Factors
- Hurdles: Prescriber familiarity, interchangeability recognition, and reimbursement policies.
- Accelerators: Demonstrated biosimilarity, strong payer negotiations, and formulary listing.
- Barriers: Patent litigation delays, manufacturing capacity constraints, and market hesitations.
Regulatory Considerations
- The FDA’s biosimilar guidance emphasizes comparability and demonstrate no clinically meaningful differences.
- Interchangeability status affects substitution practices and market share.
- Market access is sensitive to state-level legislation on biosimilar substitution.
Key Drivers of Price Trends
| Indicator |
Effect |
| Expiry of biologic patents |
Facilitates biosimilar market entry |
| Payer preference and policies |
Promote biosimilar adoption, pressure prices |
| Manufacturer strategies |
Launch, rebate, and contracting tactics |
| Regulatory updates |
Clarify interchangeability, labeling, and promotion |
Key Takeaways
- The drug coded as NDC 72603-0810 is positioned within the biosimilar segment, competing against established biologics.
- Market prices are currently discounting originators by 20-30%, with future decreases likely as competition and biosimilar availability increase.
- Pricing is heavily influenced by patent statuses, regulatory developments, and payer dynamics.
- The mid-term outlook suggests consistent pressure on prices driven by increased biosimilar approvals and adoption.
FAQs
1. How does patent expiration impact the pricing of NDC 72603-0810?
Patent expiration enables biosimilar entry, increasing competition and contributing to lower prices. Prices typically decrease 20-35% after patent expiry.
2. Will biosimilars like NDC 72603-0810 be interchangeable with the originator?
Interchangeability depends on FDA designation. If approved as interchangeable, substitution at pharmacies can occur without prescriber approval, possibly increasing market share and reducing prices.
3. What factors could cause prices to rise in the biosimilar market?
Supply chain constraints, manufacturing issues, or regulatory delays could reduce competition. Also, if biosimilars face patent litigations, prices could temporarily increase.
4. How do payer policies influence the market price of NDC 72603-0810?
Payers favor biosimilars for cost savings. Preference policies and formulary inclusion tend to increase utilization, encouraging price discounts and negotiations.
5. What are the risks associated with investing in biosimilar development?
Regulatory delays, patent disputes, limited market acceptance, and manufacturing challenges make biosimilar investments risky despite growth prospects.
Sources:
[1] IQVIA. (2022). Biologics and biosimilars market analysis.
[2] U.S. Food and Drug Administration. (2022). Biosimilar guidance documents.
[3] EvaluatePharma. (2022). 2022 biologics pricing and market data.
